Yale Cancer Center Study Shows Long-Term Survival Benefit for Certain Patients with Advanced Lung Cancer

According to the results of a large, global study led by Yale Cancer Center researchers, even a tiny amount of a biomarker known as PD-L1 (programmed death-ligand1) can predict a long-term survival benefit from using pembrolizumab (Keytruda).

Yale Cancer Center launches Center for Community Engagement and Health Equity

Yale Cancer Center (YCC) announces the launch of the Center for Community Engagement and Health Equity (CEHE). Building on YCC’s longstanding commitment to high-quality, expert, and patient-centered cancer care, screening, and prevention across the state of Connecticut, the new Center is dedicated to ensuring cancer health equity and improving outcomes with an emphasis on traditionally underserved neighborhoods.

Yale Cancer Center study suggests new approaches needed to manage ibrutinib-related toxicities in CLL patients

New findings by Yale Cancer Center (YCC) and Smilow Cancer Hospital researchers show that as the use of the drug ibrutinib climbs in patients with chronic lymphocytic leukemia (CLL), so do the rates of patients who stop taking the drug.

Yale Cancer Center researchers show identifying type of chronic pain in adults with sickle cell disease may lead to better outcomes

Identifying the type of pain an adult with sickle cell disease (SCD) experiences may be useful in improving treatment, according to a new study by researchers at Yale Cancer Center (YCC) and Smilow Cancer Hospital.

Smilow Cancer Hospital expert explains five things you need to know about Lung Cancer

Roy Herbst, M.D., Ph.D., chief of Medical Oncology at Smilow Cancer Hospital, has been researching lung cancer and treating patients with the disease for more than 25 years. He discusses the facts about lung cancer, ways to reduce your risk, and how new treatments are significantly extending life for patients.